YTTRIUM (90 Y)

Liver Cancer

M.D. Anderson Cancer CenterOtherPhase 1Active

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

110 Active assets in the Liver Cancer cohort.

Asset / Sponsor	Phase	Rating
Dexmedetomidine Uppsala University Hospital	Phase 4	BBB
DOXORUBICIN Shanghai Zhongshan Hospital	Phase 4	BB
OXALIPLATIN Sun Yat-sen University	Phase 3	BB
S-Ketamine The Second Affiliated Hospital of Chongqing Medical University	Phase 4	BB
Gardasil 9 Vaccine Eunice Dube	Phase 4	BB

View all 50 →

Same molecule, other indications

YTTRIUM (90 Y) is also rated in:

hepatocellular carcinomaActive

B

Indicative · Phase 3

58 / 100

disease related to solid organ transplantationActive

CCC

Indicative · Phase 1/2

48 / 100

metastatic neoplasmActive

CC

Indicative · Phase 1

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.